ASCO GI 2020: Zanidatamab showed long-lasting anti-tumor activity in treated HER2 plus gastroesophageal adenocarcinoma patients

Studies presented at the ASCO GI 2020 conference have shown that Zanidatamab can be used as both a single drug and in combination with chemotherapy to have good tolerance and anti-tumor activity in patients with gastroesophageal adenocarcinoma who are positive for therapeutic epidermal growth factor 2 (HER2).
, of the University of Texas at Anderson Cancer Center, explains: "Zanidatamab is a bistone antibody against HER2.
it also binds to two different bits on HER2 extracellular IV.
this unique combination leads to multiple mechanisms of action".
In Parts 1 and 2 of the Phase I study, the patient received zanidatamab monotherapy (n s 36), and in part 3 of the study, the patient received the treatment of zandatamab combined with yew alcohol or capedabin (n s 26).
most patients have previously received at least 2 systemic treatments, including curtoju monotherapy.
, Dr Meric-Bernstam, said: "Overall, the objective remission rate was 33 per cent, the disease control rate was 61 per cent and the response duration was six months.
patients treated with zandatamab combined with yew alcohol or carpedabin, the objective remission rates were 50 per cent and 57 per cent, respectively, and the disease control rates were 90 per cent and 71 per cent, respectively.
response duration was 9 months and 5.8 months, respectively."